Clinical Trial Update: Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) study evaluating pucotenlimab in combination with lenvatinib and the SOX regimen versus SOX alone in HER2-negative advanced gastric or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• OXALIPLATIN (Oxaliplatin)
• Pucotenlimab
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Fujian Medical University | Conditions: Gastric (Stomach) Cancer | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION